Loading...
XNAS
NTRA
Market cap19bUSD
Jul 24, Last price  
141.07USD
1D
2.35%
1Q
-8.27%
Jan 2017
1,104.65%
IPO
541.20%
Name

Natera Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
11.35
EPS
Div Yield, %
Shrs. gr., 5y
12.39%
Rev. gr., 5y
41.20%
Revenues
1.70b
+56.75%
14,250,00055,171,000159,289,000190,355,000217,074,000210,939,000257,654,000302,328,000391,005,000625,486,000820,222,0001,082,571,0001,696,911,000
Net income
-190m
L-56.20%
-76,171,000-37,110,000-5,152,000-70,275,000-95,765,000-136,314,000-128,154,000-124,827,000-229,743,000-471,716,000-547,799,000-434,801,000-190,426,000
CFO
136m
P
-14,905,000-24,132,00010,490,000-37,832,000-73,902,000-96,792,000-70,581,000-63,444,000-182,512,000-335,236,000-431,501,000-246,955,000135,664,000
Earnings
Aug 06, 2025

Profile

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
IPO date
Jul 02, 2015
Employees
2,958
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,696,911
56.75%
1,082,571
31.99%
820,222
31.13%
Cost of revenue
1,077,891
910,509
772,671
Unusual Expense (Income)
NOPBT
619,020
172,062
47,551
NOPBT Margin
36.48%
15.89%
5.80%
Operating Taxes
695
271
978
Tax Rate
0.11%
0.16%
2.06%
NOPAT
618,325
171,791
46,573
Net income
(190,426)
-56.20%
(434,801)
-20.63%
(547,799)
16.13%
Dividends
Dividend yield
Proceeds from repurchase of equity
41,369
235,441
446,229
BB yield
-0.21%
-3.27%
-11.29%
Debt
Debt current
90,530
92,023
80,350
Long-term debt
203,344
416,995
434,807
Deferred revenue
19,128
20,001
Other long-term liabilities
24,682
(20,078)
Net debt
(674,402)
(369,959)
(383,149)
Cash flow
Cash from operating activities
135,664
(246,955)
(431,501)
CAPEX
(66,423)
(39,199)
(47,697)
Cash from investing activities
137,624
168,498
330,338
Cash from financing activities
30,204
254,461
482,640
FCF
551,900
83,595
(66,777)
Balance
Cash
968,276
878,977
898,306
Long term investments
Excess cash
883,430
824,848
857,295
Stockholders' equity
(2,568,194)
(2,380,510)
(1,958,986)
Invested Capital
3,975,414
3,606,958
3,098,914
ROIC
16.31%
5.12%
1.68%
ROCE
43.99%
14.03%
4.10%
EV
Common stock shares outstanding
124,718
114,997
98,408
Price
158.30
152.71%
62.64
55.94%
40.17
-56.99%
Market cap
19,742,859
174.08%
7,203,412
82.22%
3,953,049
-53.26%
EV
19,068,457
6,833,453
3,569,900
EBITDA
649,988
196,159
64,253
EV/EBITDA
29.34
34.84
55.56
Interest
12,638
9,319
Interest/NOPBT
7.35%
19.60%